Clinical Trials
4 trialsNCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
NCT03516214 2024-02-15
EATON
University of Cologne
Phase 1 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed